Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Sanofi save search
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
Published: 2023-03-13 (Crawled : 07:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 241.08%
H: 0.62%
C: 0.08%
treatment acquire diabetes sanofi
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 241.08%
H: 0.62%
C: 0.08%
conference year
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
Published: 2023-09-14 (Crawled : 10:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.14%
H: 0.0%
C: -1.3%
FWBI | $3.04 -2.56% -2.63% 37K
|
Manufacturing
|
| O: 109.38%
H: 21.84%
C: -44.24%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.26%
H: 0.74%
C: 0.33%
license biopharma global agreement sanofi
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 47.44%
H: 0.0%
C: 0.0%
topline positive results study
IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi
Published: 2022-03-29 (Crawled : 07:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
|
| O: 42.23%
H: 68.76%
C: 38.32%
conference collaboration
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
Published: 2022-03-29 (Crawled : 09:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
|
| O: 42.23%
H: 68.76%
C: 38.32%
collaboration immunology
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Published: 2022-03-29 (Crawled : 11:00) - globenewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
|
| O: 42.23%
H: 68.76%
C: 38.32%
results
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
Published: 2022-12-14 (Crawled : 19:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.88%
H: 0.48%
C: -0.21%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: 0.0%
KYMR | $35.18 -1.48% -1.51% 380K
|
Health Technology
|
| O: 31.57%
H: 0.68%
C: -12.91%
kt-474 trials trial positive results
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
Published: 2021-08-03 (Crawled : 06:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.54%
H: 0.29%
C: -0.16%
TBIO | $0.311 -3.86% -4.02% 130K
|
Health Technology
|
| O: 29.16%
H: 0.21%
C: 0.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.31%
H: 0.22%
C: 0.12%
vaccine technology
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Published: 2023-09-05 (Crawled : 11:00) - prnewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.38%
H: 0.42%
C: -1.2%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: 26.82%
H: 4.34%
C: -6.03%
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 0.22%
H: 2.39%
C: -7.8%
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Published: 2022-10-06 (Crawled : 12:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 24.09%
H: 0.0%
C: 0.0%
diabetes agreement therapy sanofi
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 24.09%
H: 0.0%
C: 0.0%
teplizumab diabetes potential sanofi
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
Published: 2023-03-08 (Crawled : 13:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
OPK | $1.225 -2.0% -2.04% 6.1M
|
Health Technology
|
| O: 20.75%
H: 3.13%
C: -11.72%
candidate collaboration vaccine license virus therapeutics agreement
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
Published: 2023-05-09 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: 0.0%
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: 20.4%
H: 26.64%
C: 6.13%
covid vaccine positive influenza topline results show
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Published: 2024-02-27 (Crawled : 13:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
DNLI | $15.55 -3.48% -3.6% 940K
|
Health Technology
|
| O: 18.06%
H: 17.95%
C: 17.1%
business year therapeutics financial results
Form DEF 14A Blend Labs, Inc. For: Jun 15 – StreetInsider.com
Published: 2023-05-01 (Crawled : 12:00) - spacfeed.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 4.08%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 17.21%
H: 1.92%
C: 1.39%
IVERIC BIO, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K) – Marketscreener.com
Published: 2023-05-01 (Crawled : 12:00) - spacfeed.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 4.08%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 17.21%
H: 1.92%
C: 1.39%
change financial
Razor Announces Recapitalization Transaction Including Debt Settlement and Rights Offering to All Common Shareholders – Marketscreener.com
Published: 2023-05-01 (Crawled : 12:00) - spacfeed.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 4.08%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 17.21%
H: 1.92%
C: 1.39%
offering
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
Published: 2022-09-08 (Crawled : 13:20) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
trials global
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Published: 2022-09-08 (Crawled : 16:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.